MedTrace Logo

Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy

NCT04042623 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-02-10

Study results available
· View outcomes & findings →

Summary

This is an open-label Phase 2a clinical study designed to evaluate the safety and efficacy of AVB-S6-500 in patients with IgA Nephropathy (IgAN). Approximately 24 patients will be enrolled. Several dose levels of AVB-S6-500 may be evaluated.

Conditions

Interventions

DRUG

AVB-S6-500

AVB-S6-500 is experimental drug

Sponsors & Collaborators

  • Aravive, Inc.

    lead INDUSTRY

Principal Investigators

  • Francoise Desir · Aravive, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-27
Primary Completion
2020-08-01
Completion
2020-08-01
FDA Drug
Yes

Countries

  • United States
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04042623 on ClinicalTrials.gov